| 334.03 Delayed Data As of Apr 22 |  +0.69 / +0.21%Today’s Change | 281.89 Today|||52-Week Range 442.00 | -10.57% Year-to-Date |
| Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran Apr 16 / Zacks.com - Paid Partner Content | Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran Apr 15 / Zacks.com - Paid Partner Content |
| Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA Apr 16 / Zacks.com - Paid Partner Content | 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Apr 11 / Zacks.com - Paid Partner Content |
| Is Alnylam Pharmaceuticals a Buy Now? Apr 16 / MotleyFool.com - Paid Partner Content | Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Apr 10 / Zacks.com - Paid Partner Content |
| Previous close | 333.34 |
| Today’s open | 332.50 |
| Day’s range | 329.00 - 336.00 |
| Volume | 921,746 |
| Average volume (3 months) | 751,227 |
| Market cap | $35.8B |
| Earnings growth (last year) | +100.98% |
| Earnings growth (this year) | +0.98% |
| Earnings growth (next 5 years) | +11.00% |
| Revenue growth (last year) | +14.28% |
| P/E ratio | 15.7 |
| Price/Sales | 6.39 |
| Price/Book | 4.15 |
| Today’s change | Today’s % change | |
|---|---|---|
| BAXBaxter International... | +0.92 | +1.24% |
| VRTXVertex Pharmaceutica... | +0.36 | +0.21% |
| ALXNAlexion Pharmaceutic... | +2.95 | +2.34% |
| AGNAllergan | -0.05 | -0.04% |
| Next reporting date | May 7, 2019 |
| EPS forecast (this quarter) | $5.41 |
| Annual revenue (last year) | $6.7B |
| Annual profit (last year) | $2.4B |
| Net profit margin | 36.42% |
Sector Health Technology |
Industry Biotechnology |
Co-President, Chief Executive Officer & Director Leonard S. Schleifer |
Co-President, Director & Chief Scientific Officer George Damis Yancopoulos |
Corporate headquarters Tarrytown, New York |
